Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alector Inc (NQ: ALEC )

5.320 -0.070 (-1.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 247,499
Open 5.450
Bid (Size) 4.790 (1)
Ask (Size) 5.550 (3)
Prev. Close 5.390
Today's Range 5.280 - 5.550
52wk Range 3.660 - 9.065
Shares Outstanding 83,351,778
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace

Performance

YTD
-33.42%
-33.42%
1 Month
-8.90%
-8.90%
3 Month
-11.19%
-11.19%
6 Month
-2.74%
-2.74%
1 Year
-32.91%
-32.91%

More News

Read More
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Recap: Alector Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
Earnings Outlook For Alector
Via Benzinga
Why Alector (ALEC) Stock Is Diving Today
Via Benzinga
Expert Ratings for Alector
Via Benzinga
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
From Alector, Inc.
Via GlobeNewswire
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
From Alector, Inc.
Via GlobeNewswire
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Via InvestorPlace
Alector Announces Closing of Public Offering
From Alector, Inc.
Via GlobeNewswire
SolarEdge Technologies, Calavo Growers, Fisker And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Alector Announces Pricing of Public Offering of Common Stock
From Alector, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Alector Announces Proposed Public Offering of Common Stock
From Alector, Inc.
Via GlobeNewswire
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Alector Upgraded, Analyst Sees High Reward Potential Ahead of Alzheimer's Disease Candidate's Phase 2 Results
Via Benzinga
Jabil Posts Upbeat Earnings, Joins Moderna, Rivian Automotive And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Harmonic To Rally Over 80%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.